Mark Tawa

Performance comparison of a co-crystal of carbamazepine with marketed product

Magali B. Hickey, Matthew L. Peterson, Lisa A. Scoppettuolo et al. · European Journal of Pharmaceutics and Biopharmaceutics · 2006 · 385 citations

Marketed Product, Medicinal Chemistry, Medicine +4

Combined Use of Crystalline Salt Forms and Precipitation Inhibitors to Improve Oral Absorption of Celecoxib from Solid Oral Formulations

Héctor R. Guzmán, Mark Tawa, Zhong Zhang et al. · Journal of Pharmaceutical Sciences · 2007 · 373 citations

Pharmaceutical Science, Crystalline Salt Forms, Medicine +6

High-Throughput Surveys of Crystal Form Diversity of Highly Polymorphic Pharmaceutical Compounds

Örn Almarsson, Magali B. Hickey, Matthew L. Peterson et al. · Crystal Growth & Design · 2003 · 79 citations

Combinatorial Chemistry, Medicinal Chemistry, Crystal Form Diversity +15

Improving the Gastrointestinal Tolerability of Fumaric Acid Esters: Early Findings on Gastrointestinal Events with Diroximel Fumarate in Patients with Relapsing-Remitting Multiple Sclerosis from the Phase 3, Open-Label EVOLVE-MS-1 Study

Michael J. Palte, Angela Wehr, Mark Tawa et al. · Advances in Therapy · 2019 · 60 citations · Full text

Celecoxib sodium salt: engineering crystal forms for performance

Julius F. Remenar, Mark Tawa, Matthew L. Peterson et al. · CrystEngComm · 2010 · 17 citations

Engineering, Chemistry, Celecoxib Sodium Salt +17